Literature DB >> 8515136

Prevention of acute and chronic liver disease through immunization: hepatitis B and beyond.

H S Margolis1.   

Abstract

Liver disease caused by hepatotrophic viruses imposes a substantial burden on health care resources. Persistent infections from hepatitis B virus (HBV), hepatitis C virus, and hepatitis delta virus result in chronic liver disease, while hepatitis A virus and hepatitis E virus produce a self-limited disease. Effective hepatitis B vaccines that provide long-term protection against chronic HBV infection have been available for > 10 years, while inactivated hepatitis A vaccines have recently been shown to prevent acute disease. To prevent transmission of HBV, scientifically and epidemiologically sound recommendations call for vaccination of all infants in successive birth cohorts worldwide. For hepatitis A vaccines, recommendations will be developed in the near future and should reflect vaccine performance and the epidemiology of hepatitis A. A number of policy, health care financing, and educational issues must be addressed to ensure the effective use of both of these vaccines.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8515136     DOI: 10.1093/infdis/168.1.9

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Hepatitis.

Authors:  M Krajden
Journal:  Can J Infect Dis       Date:  2001-11

2.  Relationship between T-lymphocyte cytokine levels and sero-response to hepatitis B vaccines.

Authors:  Vijayakumar Velu; Shanmugam Saravanan; Subhadra Nandakumar; Esaki-Muthu Shankar; Appasamy Vengatesan; Suresh-Sakharam Jadhav; Prasad-Suryakant Kulkarni; Sadras-Panchatcharam Thyagarajan
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

3.  Epidemiology of childhood hepatitis B in India: vaccination related issues.

Authors:  L Kant; A J Hall
Journal:  Indian J Pediatr       Date:  1995 Nov-Dec       Impact factor: 1.967

4.  Analysis of human T-cell antigen receptor variable beta gene usage following vaccination with recombinant HBsAg.

Authors:  K Yuh; S Sugyo; K Nakamura; H Shijo; K Emi; K Harada; S Yoshitake; N Kimura; T Moribe; T Kaneshige; M Okumura
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

Review 5.  Surveillance and prevention of hepatitis B virus transmission.

Authors:  N Smith; H Yusuf; F Averhoff
Journal:  Am J Public Health       Date:  1999-01       Impact factor: 9.308

Review 6.  Hepatitis B vaccine: a pharmacoeconomic evaluation of its use in the prevention of hepatitis B virus infection.

Authors:  S M Holliday; D Faulds
Journal:  Pharmacoeconomics       Date:  1994-02       Impact factor: 4.981

7.  Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas.

Authors:  W J Edmunds; G F Medley; D J Nokes; C J O'Callaghan; H C Whittle; A J Hall
Journal:  Epidemiol Infect       Date:  1996-10       Impact factor: 2.451

8.  RECOMMENDATION FOR HEPATITIS - B VACCINATION.

Authors:  A Bahadur; S K Dham
Journal:  Med J Armed Forces India       Date:  2017-06-27

9.  The laboratory diagnosis of hepatitis B virus.

Authors:  Mel Krajden; Gail McNabb; Martin Petric
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-03       Impact factor: 2.471

Review 10.  Comprehensive control (or elimination) of hepatitis B virus transmission in the United States.

Authors:  F B Hollinger
Journal:  Gut       Date:  1996       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.